A Phase 1, Double Blind, Third-Party Open, Randomized, Placebo Controlled, Single And Multiple Dose, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-06687234 In Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2016
At a glance
- Drugs F8 IL10 (Primary) ; F8 IL10 (Primary)
- Indications Inflammation; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Pfizer
- 04 Nov 2016 Status changed from recruiting to discontinued.
- 25 Jul 2016 Planned End Date changed from 1 Nov 2017 to 1 Aug 2017.
- 25 Jul 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Aug 2017.